Rua Life Sciences Liabilities 2024

Rua Life Sciences Aktienanalyse

What does Rua Life Sciences do?

Rua Life Sciences PLC is a British company specializing in the development and manufacture of therapeutics and medical devices in the pharmaceutical industry. It was founded in 1999 by Dr. Ahmed Abdullah as Research Chemicals International. In 2007, it was renamed Rua Life Sciences PLC and has been listed on the London Stock Exchange since 2014. The business model of Rua Life Sciences PLC is the research and development of pharmaceuticals. The company invests in the discovery of new active substances and technologies that can be used to treat diseases. In addition, Rua Life Sciences PLC is also involved in the storage and transportation of pharmaceutical products. The product range of Rua Life Sciences PLC includes various areas such as oncology, neurology, ophthalmology, infectious diseases, and cardiovascular diseases. In oncology research, the company works on innovative approaches to the treatment of various types of cancer. This includes the development of drugs to combat breast cancer or lung cancer. In neurology, Rua Life Sciences PLC aims to develop new therapeutics for the treatment of diseases of the nervous system. This includes, among other things, drugs for the relief of Parkinson's or Alzheimer's. In the field of ophthalmology, the company researches drugs for the treatment of eye diseases such as macular degeneration, which leads to vision impairment in older people. This also includes testing new technologies such as the combination of drugs with special apparatus. In infectious diseases research, Rua Life Sciences PLC works on drugs to combat viruses and bacteria that can cause various diseases. This also includes the development of vaccines to counter epidemic outbreaks. Another important area for Rua Life Sciences PLC is research in the field of cardiovascular diseases. The company is working on drugs to treat hypertension, heart attacks, and other cardiovascular diseases. In addition to pharmaceutical products and therapeutics, Rua Life Sciences PLC also offers medical devices. These include blood glucose meters and medical inhalers used in the treatment of respiratory diseases. The company aims to help patients worldwide and save lives. It invests large sums in the research and development of therapeutics and medical devices to improve healthcare for humans and animals. Rua Life Sciences PLC collaborates with leading scientists and biomedical companies and maintains a network of partners around the world. Overall, Rua Life Sciences PLC is a company with a wide product range specializing in the manufacture of pharmaceuticals and medical devices. The company is committed to healing diseases and improving the health of people worldwide. Rua Life Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Rua Life Sciences's Liabilities

Rua Life Sciences's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Rua Life Sciences's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Rua Life Sciences's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Rua Life Sciences's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Rua Life Sciences’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Rua Life Sciences stock

What is the level of liabilities of Rua Life Sciences this year?

Rua Life Sciences has a debt balance of 986,999.99 GBP this year.

What were the liabilities of Rua Life Sciences compared to the previous year?

The liabilities of Rua Life Sciences have increased by -5.1% dropped compared to the previous year.

What are the consequences of high debt for investors of Rua Life Sciences?

High liabilities can pose a risk for investors of Rua Life Sciences, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Rua Life Sciences?

Low liabilities mean that Rua Life Sciences has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Rua Life Sciences affect the company?

An increase in liabilities of Rua Life Sciences can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Rua Life Sciences affect the company?

A decrease in the liabilities of Rua Life Sciences can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Rua Life Sciences?

Some factors that can influence the liabilities of Rua Life Sciences include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Rua Life Sciences so important for investors?

The liabilities of Rua Life Sciences are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Rua Life Sciences take to modify the liabilities?

To change its liabilities, Rua Life Sciences can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Rua Life Sciences pay?

Over the past 12 months, Rua Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Rua Life Sciences is expected to pay a dividend of 0 GBP.

What is the dividend yield of Rua Life Sciences?

The current dividend yield of Rua Life Sciences is .

When does Rua Life Sciences pay dividends?

Rua Life Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Rua Life Sciences?

Rua Life Sciences paid dividends every year for the past 0 years.

What is the dividend of Rua Life Sciences?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Rua Life Sciences located?

Rua Life Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Rua Life Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Rua Life Sciences from 12/18/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.

When did Rua Life Sciences pay the last dividend?

The last dividend was paid out on 12/18/2024.

What was the dividend of Rua Life Sciences in the year 2023?

In the year 2023, Rua Life Sciences distributed 0 GBP as dividends.

In which currency does Rua Life Sciences pay out the dividend?

The dividends of Rua Life Sciences are distributed in GBP.